2,2'-Dipyrazinylether | 56107-19-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 2,2'-Dipyrazinylether
• 英文别名: 2,2'-oxy-bis-pyrazine；2-Pyrazin-2-yloxypyrazine
• CAS: 56107-19-8
• 化学式: C₈H₆N₄O
• 分子量: 174.162
• InChiKey: DNCBINCWTHXVOD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  60.8
• 氢给体数：
  0
• 氢受体数：
  5

文献信息

• [EN] NOVEL PIPERAZINYL-PYRAZINONE DERIVATIVES FOR THE TREATMENT OF 5-HT2A RECEPTOR-RELATED DISORDERS<br/>[FR] NOUVEAUX DERIVES DE PIPERAZINYL-PYRAZINONE POUR LE TRAITEMENT DES TROUBLES LIES AU RECEPTEUR 5-HT2A
  申请人：BIOVITRUM AB

  公开号：WO2004009586A1

  公开（公告）日：2004-01-29

  Compounds of the general formula (I): (I)wherein m, n, R1, R2, R3 and R4 are as described in the specification. Further included are pharmaceutical compositions comprising the compounds, processes for their preparation, as well as the use of the compounds for the preparation of a medicament for the treatment of 5-HT2A receptor-related disorders or medical conditions.

  通式（I）的化合物：（I）其中m、n、R1、R2、R3和R4如规范中所述。还包括包含这些化合物的药物组合物，它们的制备方法，以及利用这些化合物制备用于治疗5-HT2A受体相关疾病或医疗状况的药物的用途。
• HETEROCYCLIC ANTIVIRAL COMPOUNDS
  申请人：Steiner Sandra

  公开号：US20100158860A1

  公开（公告）日：2010-06-24

  Compounds having the formula I wherein A, R 1 , R 2 , R 3 , R 4a , R 4b , R 4c , R 5 , R 6 , R 7a , R 7b , Ar 1 , R c , R d , R e , R f , X, n and p are as defined herein are Hepatitis C virus NS5b polymerase inhibitors. Also disclosed are compositions and methods for treating an HCV infection and inhibiting HCV replication.

  具有以下公式I的化合物，在该公式中A、R1、R2、R3、R4a、R4b、R4c、R5、R6、R7a、R7b、Ar1、Rc、Rd、Re、Rf、X、n和p的定义如本文所述，是丙型肝炎病毒NS5b聚合酶抑制剂。还公开了用于治疗HCV感染和抑制HCV复制的组合物和方法。
• Compounds
  申请人：——

  公开号：US20040063693A1

  公开（公告）日：2004-04-01

  Compounds of the general formula (I): 1 wherein m, n, R 1 , R 2 , R 3 and R 4 are as described in the specification. Further included are pharmaceutical compositions comprising the compounds, processes for their preparation, as well as the use of the compounds for the preparation of a medicament for the treatment of 5-HT 2A receptor-related disorders or medical conditions.

  通式（I）的化合物：其中m，n，R1，R2，R3和R4如说明书所述。还包括包含这些化合物的制药组合物，它们的制备过程，以及使用这些化合物制备治疗5-HT2A受体相关疾病或医疗条件的药物的方法。
• TETRAHYDRONAPHTHYRIDINE AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE
  申请人：Merck Sharp & Dohme Corp.

  公开号：US20150111877A1

  公开（公告）日：2015-04-23

  The invention provides tetrahydronaphthyridine and related compounds, pharmaceutical compositions, methods of inhibiting RORγ activity, reducing the amount of IL-17 in a subject, and treating immune disorders and inflammatory disorders using such tetrahydronaphthyridine and related compounds.

  本发明提供四氢萘啶及相关化合物、制药组合物、抑制RORγ活性、减少受试者体内IL-17含量、以及使用这种四氢萘啶及相关化合物治疗免疫性疾病和炎症性疾病的方法。
• Tetrahydronaphthyridine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease
  申请人：Merck Sharp & Dohme Corp.

  公开号：US10377768B2

  公开（公告）日：2019-08-13

  The invention provides tetrahydronaphthyridine and related compounds, pharmaceutical compositions, methods of inhibiting RORγ activity, reducing the amount of IL-17 in a subject, and treating immune disorders and inflammatory disorders using such tetrahydronaphthyridine and related compounds.

  本发明提供了四氢萘啶及相关化合物、药物组合物、抑制 RORγ 活性的方法、降低受试者体内 IL-17 含量的方法，以及使用此类四氢萘啶及相关化合物治疗免疫紊乱和炎症性疾病的方法。